Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.3390/molecules25102424

http://scihub22266oqcxt.onion/10.3390/molecules25102424
suck pdf from google scholar
32455942!7287953!32455942
unlimited free pdf from europmc32455942    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid32455942      Molecules 2020 ; 25 (10): ä
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Potential Therapeutic Targeting of Coronavirus Spike Glycoprotein Priming #MMPMID32455942
  • Barile E; Baggio C; Gambini L; Shiryaev SA; Strongin AY; Pellecchia M
  • Molecules 2020[May]; 25 (10): ä PMID32455942show ga
  • Processing of certain viral proteins and bacterial toxins by host serine proteases is a frequent and critical step in virulence. The coronavirus spike glycoprotein contains three (S1, S2, and S2') cleavage sites that are processed by human host proteases. The exact nature of these cleavage sites, and their respective processing proteases, can determine whether the virus can cross species and the level of pathogenicity. Recent comparisons of the genomes of the highly pathogenic SARS-CoV2 and MERS-CoV, with less pathogenic strains (e.g., Bat-RaTG13, the bat homologue of SARS-CoV2) identified possible mutations in the receptor binding domain and in the S1 and S2' cleavage sites of their spike glycoprotein. However, there remains some confusion on the relative roles of the possible serine proteases involved for priming. Using anthrax toxin as a model system, we show that in vivo inhibition of priming by pan-active serine protease inhibitors can be effective at suppressing toxicity. Hence, our studies should encourage further efforts in developing either pan-serine protease inhibitors or inhibitor cocktails to target SARS-CoV2 and potentially ward off future pandemics that could develop because of additional mutations in the S-protein priming sequence in coronaviruses.
  • |Animals[MESH]
  • |Antigens, Bacterial/toxicity[MESH]
  • |Antiviral Agents/*pharmacology/therapeutic use[MESH]
  • |Bacterial Toxins/toxicity[MESH]
  • |Betacoronavirus/pathogenicity[MESH]
  • |Binding Sites[MESH]
  • |COVID-19[MESH]
  • |Coronavirus Infections/*drug therapy[MESH]
  • |Drug Delivery Systems[MESH]
  • |Female[MESH]
  • |Furin/pharmacology[MESH]
  • |Humans[MESH]
  • |Mice[MESH]
  • |Mice, Inbred BALB C[MESH]
  • |Models, Molecular[MESH]
  • |Pandemics[MESH]
  • |Pneumonia, Viral/*drug therapy[MESH]
  • |RAW 264.7 Cells[MESH]
  • |SARS-CoV-2[MESH]
  • |Serine Proteases/*metabolism[MESH]
  • |Serine Proteinase Inhibitors/*pharmacology/therapeutic use[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box